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Abstract
Background: One third to two thirds of people with schizophrenia have persistent psychotic
symptoms despite clozapine treatment. Under real-world circumstances, the need to provide
effective therapeutic interventions to patients who do not have an optimal response to clozapine
has been cited as the most common reason for simultaneously prescribing a second antipsychotic
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Trials 2009, 10:31 http://www.trialsjournal.com/content/10/1/31drug in combination treatment strategies. In a clinical area where the pressing need of providing
therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy,
despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol
where two alternative therapeutic answers are systematically provided and evaluated within the
context of a pragmatic, multicentre, independent randomised study.
Methods/Design: The principal clinical question to be answered by the present project is the
relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole
compared with combination treatment with clozapine plus haloperidol in patients with an
incomplete response to treatment with clozapine over an appropriate period of time. This project
is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over
a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary
outcome.
Discussion: The implementation of the protocol presented here shows that it is possible to create
a network of community psychiatric services that accept the idea of using their everyday clinical
practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly
allocate more than 100 individuals, which means that this study is the largest antipsychotic
combination trial conducted so far in Western countries. We expect that the current project, by
generating evidence on whether it is clinically useful to combine clozapine with aripiprazole rather
than with haloperidol, provides physicians with a solid evidence base to be directly applied in the
routine care of patients with schizophrenia.
Trial Registration: Clincaltrials.gov Identifier: NCT00395915
Background
Schizophrenia is a disabling mental disorder [1]. It affects
as much as 1% of the population worldwide and it is char-
acterised by psychotic symptoms, including delusions and
hallucinations, negative symptoms, characterised by "loss
of function", and cognitive impairment [2].
A proportion of one fifth to one third of patients with
schizophrenia derive little or no benefit from treatment
with conventional or novel antipsychotics [3]. In these
treatment-refractory patients, e.g. individuals who had
not responded, or had intolerable side-effects, to conven-
tional and novel agents, clozapine has been shown to be
the treatment of choice [4-6]. Clozapine is, however, only
effective in producing clinically significant symptom
improvement in 30–50% of people receiving treatment.
One third to two thirds of people still have persistent psy-
chotic symptoms despite clozapine monotherapy of ade-
quate dosage, or have unwanted side-effects that do not
permit an adequate up titration of clozapine [7].
Under real-world circumstances, the need to provide
effective therapeutic interventions to patients who do not
have an optimal response to clozapine has been cited as
the most common reason for simultaneously prescribing
two or more antipsychotic drugs in combination treat-
ment strategies [8]. Similarly, adopting a pragmatic atti-
tude, European and American treatment guidelines
recognize that the concurrent prescription of a second
antipsychotic in addition to clozapine is a common-sense
strategy in these partially responsive patients [9-12]. How-
ever, it remains unclear if there is an evidence base to sup-
port one specific antipsychotic in combination with
clozapine [13-16]. In a clinical area where the pressing
need of providing therapeutic answers has progressively
increased the occurrence of antipsychotic polypharmacy,
despite the lack of robust evidence of its efficacy, we
sought to implement a pre-planned protocol where two
alternative therapeutic answers are systematically pro-
vided and evaluated within the context of a pragmatic,
multicentre, independent randomised study.
The article reported here aims at providing a description
of the following background aspects related to the devel-
opment and implementation of this project: (a) the Ital-
ian legislation on independent trials; (b) the concept of
pragmatic trials; (c) the marketing of aripiprazole, a novel
antipsychotic drug. We additionally provide a description
of the main aspects related to the design and current status
of the Clozapine plus Haloperidol or Aripiprazole Trial
(CHAT).
Italian Legislation on Independent Trials
The Italian context of care is an ideal setting for independ-
ent randomised trials, given the implementation of a
National Law (Decreto Ministeriale 17/12/04) that for-
mally recognised the public health value of independent
studies investigating the real-world effectiveness of
already marketed pharmacological treatments. In 2004 a
Ministerial Decree was issued establishing rules to helpPage 3 of 9
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In essence, the Decree states that if the following set of
conditions are met, (i) the study coordinating centre is
independent of drug company support, (ii) study results
can be disseminated autonomously, (iii) there is no per-
sonal financial interest in studying the drugs included in
the trial, (iv) the study drugs are licensed for the indica-
tion to be investigated, then the National Health Service
(NHS) materially supports the conduct of the trial in three
ways: (i) drug costs are paid by the NHS; (ii) there are no
fees for submitting the study protocol to the local Ethics
Committees; (iii) continuing medical education credits
are provided to local investigators.
Considering that all above mentioned criteria are met by
CHAT, we took fully advantage of such legislation. In par-
ticular, drug costs (clozapine, aripiprazole and haloperi-
dol) are covered by the local health authorities, with two
advantages: first, we had the possibility to carry out this
study on a low budget, independently from drug compa-
nies and from other agencies; second, the drugs under
study are prescribed in a way that is identical to that nor-
mally followed under real-word circumstances, with obvi-
ous advantages in terms of generalisability of study
findings.
Pragmatic Versus Explanatory Design
In recent years there has been a renewal of interest in prag-
matic trials (also called practical, effectiveness or manage-
ment trials), that is for studies that randomly assign real-
world patients to licensed drugs with the aim of assessing
their effectiveness [17-20]. While explanatory (or phase
III) trials answer questions about whether an intervention
can work under ideal conditions (efficacy), pragmatic (or
phase IV) trials attempt to answer questions about
whether an intervention will work in the real world.
Explanatory trials are usually carried out by the pharma-
ceutical industry, while pragmatic trials are more often
undertaken by groups of clinical researchers. Recent exam-
ples of pragmatic trials include the Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) [21] and the
Cost Utility of the Latest Antipsychotic Drugs in Schizo-
phrenia Study (CUtLASS) [22].
In Italy a seminal pragmatic study was an unblinded trial
of intravenous streptokinase in early acute myocardial inf-
arction that enrolled 11,806 patients in one hundred and
seventy-six coronary care units [23]. The first report of this
influential study was published in 1986 and in subse-
quent years there was an ongoing debate about the need
to support such research.
In the field of mental health, however, only in very recent
years criticism has focused on the current standard of the
design of explanatory clinical trials. These studies typically
enrol highly selected patients that are shortly followed
and assessed with rating scales that are seldom used in
clinical practice. In Italy this criticism has progressively
led mental health professionals to constitute research net-
works with the aim of developing pragmatic studies. Such
studies, ideally, are intended to answer real-world ques-
tions by enrolling everyday patients to be followed in the
long-term using pragmatic outcome criteria commonly
used in practice. Pragmatic measures include suicide
attempts, treatment switching, hospitalization, school
failure or truancy, job loss, or treatment discontinuation
[17,18,24]. CHAT is the first Italian example of this new
attitude [25], and other studies will soon follow [26].
Aripiprazole, a novel antipsychotic drug
In recent years the availability of newer antipsychotic
agents has increased the therapeutic options available in
the management of clozapine partial responders and,
among these newer agents, anecdotal reports have
hypothesised a promising role for aripiprazole [27,28].
Aripiprazole is a potent (high-affinity) partial agonist at
D2 and 5-HT1A receptors and a potent antagonist at 5-
HT2A receptors. In contrast to some of the other atypical
antipsychotic agents, treatment with aripiprazole appears
to be associated with minimal weight gain and minimal
negative impact on metabolic parameters, a key aspect
given that these adverse effects might occur during cloza-
pine treatment [29,30]. In terms of positive symptoms, it
has been suggested that the combination of clozapine and
aripiprazole may lead to greater D2 receptor antagonism
in mesolimbic pathways, and, additionally, may combine
D2 and D4 antagonism (although the role of D4 receptors
in antipsychotic efficacy is unclear). A challenging neuro-
biological rationale, with a highly synergistic antipsy-
chotic potency without increasing the risk of adverse
effects, has therefore been proposed [15]. Henderson and
colleagues, who conducted a six-week open label trial to
examine the effects of adjunctive aripiprazole in clozap-
ine-treated subjects, showed that this combination had
little or no effect in terms of psychotic symptoms, but was
associated with a significant decrease in weight, body
mass index, fasting total serum cholesterol and total trig-
lycerides [31]. The only randomised placebo-controlled
trial published so far, which included 62 clozapine-
treated patients with refractory schizophrenia that were
randomly assigned to double-blind combination treat-
ment with aripiprazole or placebo, showed that aripipra-
zole did not lead to better control of symptom severity
after 8 weeks of treatment, but benefits were observed in
terms of negative symptoms [32].
Other trials employed a design similar to that of CHAT,
that is pragmatically assessed the relative efficacy of com-
petitive combination strategies, including clozapine + ris-
peridone versus clozapine + sulpiride, clozapine +Page 4 of 9
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+ risperidone versus clozapine + ziprasidone [33-35].
Design and Methods
Design of The Clozapine Haloperidol Aripiprazole Trial 
(CHAT)
The principal clinical question to be answered by CHAT is
the relative effectiveness and tolerability of combination
treatment with clozapine plus aripiprazole compared to
combination treatment with clozapine plus haloperidol
in patients with an incomplete response to treatment with
clozapine over an appropriate period of time. CHAT is a
prospective, multicentre, randomized, parallel-group,
superiority trial that follows patients over a period of 12
months. Consecutive patients meeting the trial entry crite-
ria were randomly assigned to combination with aripipra-
zole or haloperidol. These patients constituted the
randomised cohort (Figure 1). Patients meeting the trial
entry criteria that were not randomly assigned to compet-
itive treatments were followed under real-world circum-
stances. These patients constituted the observational
cohort (Figure 1). In both the experimental and observa-
tional cohort patients and clinicians were not blind to
pharmacological treatments provided during the trial.
Patients will be assessed at baseline, at 3, 6 and 12 months
using the instruments reported in Figure 2.
According to Italian legislation, ethics approval was
received in each participating site. All phases of CHAT will
be recorded following the Consolidated Standard of
Reporting of Trials (CONSORT) statement [36].
Primary outcome
Withdrawal from allocated treatment within 3 months is
the primary outcome. This outcome was selected because
stopping or changing antipsychotic combination treat-
ment is a frequent occurrence and major problem in the
treatment of patients with schizophrenia. In addition,
according to Lieberman and colleagues, this measure inte-
grates patients' and clinicians' judgments of efficacy,
CHAT study design: randomised and observational cohortFigure 1
CHAT study design: randomised and observational cohort.
CLOZAPINE + ARIPIPRAZOLE
Group 3 Outcome
USUAL CARE
Patients with 
schizophrenia partially 
responsive to clozapine CLOZAPINE + HALOPERIDOL
3Page 5 of 9
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ness that reflects their evaluation of therapeutic benefits in
relation to undesirable effects [21].
Secondary outcomes
Withdrawal from allocated treatment within 12 months,
and time to withdrawal, are used to assess the overall
acceptability and efficacy over a long period of time. Addi-
tionally, severity of illness is measured by means of the
Brief Psychiatric Rating Scale (BPRS) [37]. The BPRS con-
sists of 24 items measuring the following dimensions:
positive symptoms, negative symptoms, depression/anxi-
ety and disorganization. All investigators received training
to use this rating scale. However, no formal inter-rater
exercise has been performed.
Instead of measuring adverse events as observed and
reported by the treating clinicians, CHAT measured the
perspective of patients exposed to antipsychotic agents by
means of the Liverpool University Neuroleptic Side-Effect
Rating Scale (LUNSERS) [38]. LUNSERS is a self-rated,
semi-structured interview consisting of 51 items that pro-
duces a total score that indicates the burden of side effects
as perceived by patients (subjective tolerability).
Inclusion/exclusion criteria
Patients were recruited in Italy. Community psychiatric
services agreeing to take part to the study were asked to
recruit inpatients and outpatients meeting the inclusion/
exclusion criteria over a period of 24 months. Patients
meeting the eligibility criteria and the criteria for random
allocation (see Additional file 1) were randomly allocated
to either aripiprazole or haloperidol, in combination with
clozapine, and will be followed for 12 months (experi-
mental cohort). Patients meeting the eligibility criteria,
but not the criteria for random allocation, will be fol-
lowed for 12 months under real-world circumstances and
assessed using the same assessment tools employed for
patients included in the experimental cohort (observa-
tional cohort).
Pharmacological treatments
In the experimental cohort, in order to resemble everyday
clinical practice, clinicians were allowed to prescribe the
allocated pharmacological treatments (starting dose and
dose changes) according to clinical status and circum-
stances. All dose changes will be recorded. Following ran-
domization, treatment is to be taken daily for 1 year
unless some clear reason to stop develops. Before random
allocation, patients were asked to discontinue any antip-
sychotic drugs other than clozapine. Long-acting antipsy-
chotic drugs needed to be discontinued for at least two
weeks before random allocation. All other concomitant
medications were permitted. Routine care outside the trial
continued as usual. During the study, participants are seen
as often as clinically indicated with no extra visits required
for the trial.
Study schedule: instruments and forms used at baseline and follow up-interviewsFigure 2
Study schedule: instruments and forms used at baseline and follow up-interviews.Page 6 of 9
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logical and non-pharmacological treatment as clinically
indicated. In addition, participants are seen as often as
clinically indicated with no extra visits required.
Power analysis for sample size calculation
At the time of development of the CHAT, only one antip-
sychotic trial employed discontinuation by any cause as
the primary endpoint [21]. On the basis of this trial, it was
initially hypothesised a withdrawal proportion from allo-
cated treatment within 3 months (primary study end-
point) of 25% in the group treated with clozapine plus
haloperidol (control group). Moreover, it was hypothe-
sised that the augmentation with aripiprazole (experi-
mental group) would show a clinically significant
advantage by producing a withdrawal proportion of 10%.
A sample size of 194 patients (97 in each group) was cho-
sen since it achieves 80% power to detect a difference of
15% between the two withdrawal proportions. The test
statistic used was the two-sided Z test with pooled vari-
ance. The significance level of the test was targeted at 5%.
Having assumed that 10% of the participants could be lost
within 3 months, or could not provide valid data at
month 3, the target total sample size for CHAT was 216 (=
194/0.90) patients in order to obtain 194 evaluable sub-
jects [39,40].
Having considered the possibility that the target sample
size could not be reached, we anticipated that the total
sample size at the end of the enrolment period would be
around 100 patients. With such a total sample size, CHAT
achieves 80% power to detect a difference of 20% between
the two withdrawal proportions (25% in the group
treated with clozapine plus haloperidol versus 5% in the
group treated with clozapine plus aripiprazole).
Random Allocation Procedure
Patients were randomly assigned to one of the two treat-
ment groups with an equal probability of assignment to
each treatment (allocation ratio 1:1). A centralised rand-
omization procedure was employed. The trial biostatisti-
cian prepared the sequence of treatments randomly
permuted in blocks of constant size. The site investigators
did not know the block size. The allocation was stratified
by living condition (residential facility versus all the other
living conditions) because in patients with resistant schiz-
ophrenia this hard variable may be considered a proxy of
severity of illness. Recruiting physicians were asked to
contact an operator at the World Health Organisation
Collaborative Centre of the University of Verona. The
operator had access to a computerised system that pro-
vides, after information on the enrolled participant was
entered, the patient's identification number (ID) and the
allocated treatment. The operator had not access to the
randomisation lists. This procedure of randomisation was
developed to fully conceal treatment allocation [41].
Statistical consideration
The statistical analysis will be masked, i.e. the trial biostat-
istician will be blinded to the treatment groups until the
analysis has been completed. Moreover, the trial biostatis-
tician will not be involved in determining patients' eligi-
bility, in administering the treatment, in measuring the
outcomes or in entering data.
Two data locks will occur during the study. The first one
will happen 3 months after the end of the enrolment
period, when the information on the primary endpoint
and on the short-term secondary endpoints will be avail-
able for all the participants. The second one will happen
at the end of the study (12 months after the end of the
enrolment period), when information on the long-term
secondary endpoints will be available for all participants.
Accordingly, two data analyses will be performed on an
intention-to-treat (ITT) basis. All randomised participants
who will receive at least one dose of the investigational
drugs will be included in the ITT analysis. The outcomes
of patients included in the non-randomized cohort will
be presented descriptively. No formal statistical analysis
has been planned to compare the randomized partici-
pants and the eligible, non-randomized patient cohort.
Analysis of the Primary Outcome
In the randomized cohort, the proportion of patients
withdrawing from the assigned treatment within 3
months will be compared between the two groups of
treatment through the chi-square test. Additionally, we
will calculate risk ratios and their 95% confidence inter-
vals to corroborate the main analysis. A multivariate anal-
ysis (secondary analysis) will be performed through a
Poisson regression model with a robust error variance,
given that this procedure allows to estimate relative risks
directly [42].
Status of the trial and expected achievements
The recruitment phase started on September 1st 2006 and
finished on December 31st 2008. During this period, 38
clinical sites across Italy actively participated in the study
and recruited a total of 106 patients. This means that,
despite the planned sample size of 216 patients has not
been achieved, CHAT is the largest randomised study con-
ducted so far in Western countries on this topic. Data col-
lection, study monitoring and data management are
performed by the coordinating centre (University of
Verona). All study data are entered in a computerised
database and stored by the World Health Organisation
Collaborative Centre of the University of Verona. The per-
son entering the data is not involved in determining
patients' eligibility, administering treatment, or determin-Page 7 of 9
(page number not for citation purposes)
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is ensured by the double-entry technique and by a set of
electronic and manual edit checks. The consistency of the
data between the recruitment and follow-up forms and
the computerised database are routinely verified. After
each of the two data locks, masked data will be transferred
to the Unit of Epidemiology and Medical Statistics of the
University of Verona for statistical analysis.
The main achievements of this ongoing projects include
the following: (a) the implementation of the CHAT proto-
col provides evidence that it is possible to create a network
of community psychiatric services that accept the idea of
using their everyday clinical practice to produce ran-
domised knowledge; (b) the possibility of producing
knowledge from the practice of medicine does not neces-
sarily require huge financial support, as long as a prag-
matic attitude to the evaluation of competitive treatment
strategies is adopted; (c) the multicentre design, nested
into everyday clinical practice, has been creating a situa-
tion where investigators simultaneously act both as physi-
cians and researchers; (d) the pragmatic attitude
employed allowed to randomly allocate considerable
number of individuals [43]; (e) the current project, by
generating evidence on whether it is clinically useful to
combine clozapine with aripiprazole rather than with
haloperidol, is expected to provide physicians with a solid
evidence base to be directly applied in the routine care of
patients with schizophrenia.
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